Physician profile
Lori Kim
NPI 1689891293
$3,009.40
in general payments reported to CMS, 2019-2025
16 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $111 · 2021: $530 · 2022: $461 · 2023: $713 · 2024: $361 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382 · Entertainment: $54.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.47 |
| Entertainment | $54.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,016.00 | 2022-2025 | Infuse, Biotrue One Day, Biotrue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $619.00 | 2019-2021 | |
| Optos, INC. | $251.16 | 2019-2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Sun Pharmaceutical Industries INC. | $179.63 | 2021-2025 | Cequa, Xelpros |
| Johnson & Johnson Vision Care, INC. | $154.04 | 2019-2025 | Acuvue |
| Sight Sciences, INC. | $146.81 | 2019-2023 | Tearcare System |
| Coopervision INC. | $134.93 | 2019-2025 | Misight Contact Lens |
| Alcon Vision LLC | $104.10 | 2023-2025 | Rocklatan, Total30, Tryptyr |
| Oyster Point Pharma, INC. | $97.24 | 2022-2024 | Tyrvaya |
| Allergan, INC. | $94.88 | 2020-2022 | |
| Horizon Therapeutics Plc | $87.02 | 2023 | Tepezza |
| Abbvie INC. | $51.10 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $20.11 | 2022 | |
| Amgen INC. | $18.92 | 2024 | Tepezza |
| Lkc Technologies, INC. | $18.10 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $16.36 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.